Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  The Companys beliefs regarding the advantages of the human tissues it distributes;  The Companys plans, costs, and expected timeline regarding regulatory approval for PerClot; the distribution of PerClot in certain markets after the requisite regulatory approvals are obtained; and the Companys expectation that it will terminate its minimum purchase requirements after regulatory approval of PerClot;  The Companys expectations regarding the clinical trials necessary to obtain PMA to distribute PerClot in the U.S.;  The Companys beliefs regarding the potential impact of the patent infringement litigation between CryoLife and C.R. Bard, Inc. and certain of its subsidiaries, that PerClot does not and will not infringe Medafors patent, and that the costs associated with the litigation will be significant in 2015;  The Companys beliefs regarding the potential benefits and additional applications of the Companys surgical adhesives, sealants, hemostats, revascularization technologies, HeRO Graft, and ProCol products;  The Companys belief regarding the sufficiency of its response to the 2014 CryoLife Form 483 and the Warning Letter, and that any issues related to the FDAs observations in the 2014 CryoLife Form 483 and the Warning Letter will not have a continuing material effect on the Company;  The Companys expectations regarding continued review and modification of its tissue processing and quality procedures during 2015;  The Companys plans related to regulatory approval for, and the subsequent distribution of, BioGlue in Europe;  The Companys plans related to regulatory approval in certain markets for BioFoam, and the subsequent distribution of BioFoam in those markets;  The Companys beliefs regarding the anticipated benefits of conducting a post-clearance study at the FDAs request to collect long-term clinical data for the CryoValve SGPV;  The potential impact of the FDAs review of the classification of CryoValve SGPV and the FDA advisory committees vote in favor of classifying such tissue as a class III device;  The Companys expectations regarding commencement of distribution of PhotoFix;  The Companys plans regarding HeRO Graft product enhancements;  The Companys beliefs that HeRO Graft revenues will expand in 2015, and that HeRO revenue volatility will decrease;  The Companys beliefs regarding the possibility of shipping tissues to Germany in the second half of 2015;  The Companys expectations about whether it may receive any additional payments, and if so, the timing and amount of such payments, related to its sale of Medafor stock;  The Companys expectation that general, administrative, and marketing expenses will increase in 2015 as compared to 2014, and that litigation and business development expenses could further increase these expenses;  The Companys beliefs regarding the international growth opportunities that would be provided by obtaining expanded indications for BioGlue in Japan and regulatory approval for BioGlue in China;  The Companys expectations that research and development spending will increase materially in 2015;  The Companys expectations regarding the possible bankruptcy of ValveXchange; 29 Table of Contents  The Companys anticipated payment of quarterly dividends each year;  The Companys expectations regarding the recoverability and realizability of deferred tax assets and net operating loss carryforwards;  The Companys estimates of unreported loss liabilities, including unreported product and tissue processing liability claims, the assumptions used to establish those estimates, and the Companys belief that those assumptions provide a reasonable basis for the estimates;  The Companys expectations regarding the source of any future payments related to any unreported product or tissue processing liability claims;  The Companys estimates of fair value of acquired assets, and its belief that the estimates are reasonable;  The Companys expectation that it will continue to renew certain acquired contracts and procurement agreements for the foreseeable future;  The Companys beliefs regarding the importance of, and competitive advantages associated with, its relationships with tissue procurement organizations;  The Companys belief regarding its compliance with NOTA, state licensing requirements, and environmental laws and regulations;  The Companys expectations regarding the recognition of stock compensation expense;  The Companys assessment of the effect of adopting new accounting standards regarding the recognition of revenue from contracts with customers;  The Companys plans and expectations regarding research and development of new technologies and products;  The Companys expectations regarding business consolidations in the healthcare industry that could exert downward pressure on fees charged by the Company;  The Companys belief that healthcare policy and law changes may have a material adverse effect on the business;  The Companys beliefs regarding the seasonal nature of the demand for some of its products and services;  The adequacy of the Companys financial resources and its belief that it will have sufficient cash to meet its operational liquidity needs for at least the next twelve months;  The Companys estimates of contingent payments and royalties that may be paid by the Company and the timing of such payments;  The anticipated impact on cash flows of funding business development activities and the potential need to obtain additional borrowing capacity or financing;  The anticipated impact of changes in prevailing economic conditions, interest rates, and foreign currency exchange rates;  The Companys estimates regarding specific country and worldwide market opportunities for certain types of procedures, certain types of products, and the Companys products and tissues;  The Companys beliefs and estimates regarding its competitors in various geographic, procedure, and product markets;  The Companys expectations about not triggering certain contingent payment obligations;  The Companys beliefs regarding probability of achievement of certain performance components under performance share awards granted pursuant to its stock incentive plan;  The Companys beliefs regarding the factors upon which customers base purchasing decisions and any competitive advantages or disadvantages of the Companys products or tissues relative to those of competitors;  The constraints imposed on the Company by its lender under the existing credit facility;  The Companys plans regarding acquisition and investment opportunities of complementary product lines and companies;  The Companys beliefs regarding the state of relations with its employees;  The Companys plans regarding the licensing of the Companys technology to third parties for non-competing uses;  The anticipated effect of suppliers/sources inability to deliver critical raw materials or tissues and/or the Company having to source supply from an alternate supplier;  The Companys revenue and cost trend estimates, and the underlying reasons for those trends, for its products and services for 2015; 30 Table of Contents  The Companys beliefs regarding the enhanced efficacy of certain procedures provided by using its surgical sealants;  The Companys beliefs regarding the adequacy of, and competitive advantages conferred by, its intellectual property protections;  The Companys beliefs regarding the potential for competitive products and services to affect the market for the Companys products and services;  The Companys expectations regarding the benefits of the Companys marketing, educational and technical support efforts;  The expected impacts of the Companys issuance of additional shares and share repurchases on financial results calculated on a per-share basis;  The Companys beliefs regarding the anticipated benefits of providing on-site freezers;  Issues that may affect the Companys future financial performance and cash flows; and  Other statements regarding future plans and strategies, anticipated events, or trends. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including, without limitation, in addition to those specified in the text surrounding such statements, the risk factors discussed in Item 1A of this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. 31 Table of Contents Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the Securities and Exchange Commission regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2014 (the end of the fiscal year to which this Form 10-K relates). 